DOCSLIB.ORG

NIDA - Director's Report - May 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NIDA - Director's Report - May 2004 NIDA - Director's Report - May 2004 Home > Publications > Director's Reports Director's Report to the National Advisory Council on Drug Abuse - May, 2004 Index Report Index Research Findings Report for February, 2004 Basic Research Report for Behavioral Research September, 2003 Treatment Research and Development Report for May, Research on AIDS and Other Medical Consequences of Drug 2003 Abuse - AIDS Research Report for February, Research on AIDS and Other Medical Consequences of Drug 2003 Abuse - Non-AIDS Medical Consequences of Drug Abuse Report for Epidemiology and Etiology Research September, 2002 Prevention Research Report for May, 2002 Services Research Report for February, Intramural Research 2002 Program Activities Report for September, 2001 Extramural Policy and Review Activities Report for May, 2001 Congressional Affairs Report for February, 2001 International Activities Report for September, 2000 Meetings and Conferences Report for May, 2000 Media and Education Activities Report for February, 2000 Planned Meetings Report for September, 1999 Publications Report for May, 1999 Staff Highlights Report for February, 1999 Grantee Honors Report for September, 1998 Report for May, 1998 Report for February, 1998 Report for September, 1997 Report for May, 1997 Report for February, 1997 https://archives.drugabuse.gov/DirReports/DirRep504/Default.html[11/17/16, 10:22:07 PM] NIDA - Director's Report - May 2004 Report from September, 1996 Report from May, 1996 Report from February, 1996 Report from September, 1995 Report from May, 1995 Report from February, 1995 NACDA Legislation Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep504/Default.html[11/17/16, 10:22:07 PM] NIDA - Director's Report - May, 2004 Home > Publications > Director's Reports Director's Report to the National Advisory Council on Drug Abuse - May, 2004 Research Findings - Basic Research Index Design of Novel Peptide Ligands that have Opioid Agonist Activity and CCK Research Findings Antagonist Activity for the Treatment of Pain Basic Research There is a need for a new paradigm in drug discovery for pathological conditions Behavioral Research including disease states such as neuropathic pain and conditions of opioid analgesic Treatment Research tolerance. It is now known from multiple experimental approaches that many disease and Development states lead to changes in expressed proteins (adaptation/neuroplasticity). Drug design based on normal states is inadequate or even possibly counter-indicated. Therefore Research on AIDS the system changes that have occurred must be considered in any treatment for the and Other Medical disease. Such "systems changes" are clearly evident in neuropathic pain and in Consequences of conditions of opioid tolerance where opioids can actually heighten pain. In these pain Drug Abuse - AIDS states there are increased levels and/or activity of pronociceptive neurotransmitters Research such as cholecystokinin (CCK) and their receptors. CCK and enkephalins and their Research on AIDS receptors are co-localized in the CNS and, as a pronociceptive peptide, CCK acts as an and Other Medical "antiopioid" and alternate analgesic to diminish opioid antinociception. In view of Consequences of these and other findings, NIDA grantee, Dr. Victor Hruby and colleagues have Drug Abuse - Non- investigated a new paradigm for drug discovery aimed at treatment of pathological AIDS Medical pain (such as neuropathic pain) and in conditions of opioid tolerance. In this approach Consequences of a single peptide or peptidomimetic molecule that can interact with opioid receptors as Drug Abuse agonists and at CCK receptors as antagonists is designed. Specifically, compounds Epidemiology and that are agonists at opioid mu or delta receptors and antagonists at CCK-1 or CCK-2 Etiology Research receptors (preferably both representing a "balanced" CCK receptor antagonist) are developed. It is postulated that such a molecule would show superior efficacy to Prevention Research opioid agonists for the treatment of pathological pain states since it would block the Services Research antiopioid effects of CCK and be resistant to the development of paradoxical opioid- induced pain and antinociceptive tolerance. In this paper, Dr. Hruby and his Intramural Research colleagues report progress toward these objectives using various approaches to Program Activities rational peptide ligand based drug design. De novo design based on the concept of overlapping pharmacophores was a central hypothesis of this design, and led to Extramural Policy and Review compounds such as H-Tyr-DPhe-Gly-DTrp-NMeNle-Asp-Phe-NH2 (i.e., RSA 601), Activities which have the designed properties. Hruby, V.J., Agnes, R.S., Davis, P., Ma, S-W., Lee, Y.S., Vanderah, T.W., Lai, J. and Porreca, F. Design of Novel Peptide Ligands Congressional Affairs which have Opioid Agonist Activity and CCK Antagonist Activity for the Treatment of Pain. Life Sciences 73, pp. 699-704, 2003. International Activities The Effect of Hair Color on the Incorporation of Codeine into Human Hair Meetings and Conferences The purpose of this study was to determine if codeine, as a model compound for abused drugs, would be incorporated into black, brown, blond, or red hair as a Media and Education Activities function of melanin concentration. Male and female Caucasians with black (n=6), brown (n=12), blond (n=8) or red hair (n=6) and non Caucasians with black hair Planned Meetings (n=12), aged 21-40 years of age were administered oral codeine phosphate syrup in a dose of 30 mg three times a day for five days. Twenty-four hours after the end of Publications the treatment period, a 30 mg codeine dose was administered and the subject's plasma area under the concentration time curve (AUC) for codeine was determined. Staff Highlights Codeine and melanin were measured in the first 3 cm of hair closest to scalp prior to and 1,4,5, 6,and 7 weeks after dosing. The quantitative and qualitative melanin Grantee Honors profiles were determined for each subject's hair to provide an objective measure of hair color. The plasma concentrations of codeine were measured to eliminate differences in the bioavailability and clearance of codeine as factors that might account for the differences in codeine hair concentrations. The mean hair codeine concentrations 5 weeks after dosing were 1,429 pg/mg in black hair; 208 pg/mg in brown hair; 99 pg/mg in blond hair; and 69 pg/mg in red hair. In black hair, codeine https://archives.drugabuse.gov/DirReports/DirRep504/DirectorReport1.html[11/17/16, 10:22:12 PM] NIDA - Director's Report - May, 2004 concentrations were 2,564 pg/mg for Asians and 865 pg/mg for Caucasians. Similar concentration relationships were observed at weeks 4, 6, and 7. A strong relationship between the hair concentrations of codeine and melanin was observed. These data demonstrate that the interpretation and reporting of hair test results for codeine are influenced by hair color. After this dosing protocol, the proposed federal guideline cut- off of 200 pg/mg of codeine would result in 100% of subjects with black hair and 50% of subjects with brown hair being reported as positive, and subjects with blond or red hair would be reported as negative. The incorporation of these drugs into hair should be studied carefully in humans to ensure the appropriate interpretation of drug concentrations. Rollins, D.E., Wilkins, D.G., Kruger, G.G., Augsburger, M.P., Mizuno, A., O'Neal, C., Borges, C.R. and Slawson, M.S. Journal of Analytical Toxicology, 27, pp. 545-551, 2003. Morphine Tolerance and Development In a recent paper, Dr. Gordon Barr and Dr. Hongbo Zhu report their findings on ontogeny of N-methyl-D-aspartate (NMDA) receptor mediated morphine tolerance in the postnatal rat. This study is the first to provide conclusive evidence that NMDA receptor antagonists are not effective in attenuating tolerance in the newborn rat and that there is a transition age, around the second postnatal week in the rat, for NMDA receptor antagonists to be effective in suppressing opiate tolerance and withdrawal. This study was undertaken because of the known effectiveness of NMDA receptor antagonists to inhibit the development of morphine tolerance in adults and the dramatic changes that occur in NMDA receptors during the first few weeks of postnatal life. Zhu, H. and Barr, G.A. Ontogeny of NMDA Receptor-Mediated morphine Tolerance in the Postnatal Rat. Pain. 104, pp. 437-447, 2003. Mixed Mu Agonists/Delta Antagonists There is a continuing effort and interest in developing ligands exhibiting agonist action at the mu receptor for purposes of chronic pain treatment, but which also possess antagonist properties at the delta receptor, in order to lessen or minimize the known side effects of mu ligands, such as respiratory depression and development of tolerance/dependence. Evidence has been provided by immunoprecipitation and immunoblotting results of an interaction or complex formation between mu and delta receptors, when they are co- expressed in COS cells. These co-expressed receptors showed altered binding profiles (reduced affinity of morphine, DAMGO, and DPDPE) as compared to the values reported in separate cell expressions of mu or delta receptors. Additionally, the development of acute tolerance
Load more

Recommended publications
  • S41467-020-19780-Z.Pdf
    ARTICLE https://doi.org/10.1038/s41467-020-19780-z OPEN Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice Wei Xu1,3, Hongchun Li1,3, Liang Wang1, Jiamei Zhang1, Chunqi Liu1, Xuemei Wan1, Xiaochong Liu1, Yiming Hu1, ✉ Qiyao Fang1, Yuanyuan Xiao1, Qian Bu1, Hongbo Wang2, Jingwei Tian2, Yinglan Zhao1 & Xiaobo Cen 1 The abuse potential of ketamine limits its clinical application, but the precise mechanism remains largely unclear. Here we discovered that ketamine significantly remodels the 1234567890():,; endocannabinoid-related lipidome and activates 2-arachidonoylglycerol (2-AG) signaling in the dorsal striatum (caudate nucleus and putamen, CPu) of mice. Elevated 2-AG in the CPu is essential for the psychostimulant and reinforcing effects of ketamine, whereas blockade of the cannabinoid CB1 receptor, a predominant 2-AG receptor, attenuates ketamine-induced remodeling of neuronal dendrite structure and neurobehaviors. Ketamine represses the transcription of the monoacylglycerol lipase (MAGL) gene by promoting the expression of PRDM5, a negative transcription factor of the MAGL gene, leading to increased 2-AG pro- duction. Genetic overexpression of MAGL or silencing of PRDM5 expression in the CPu robustly reduces 2-AG production and ketamine effects. Collectively, endocannabinoid signaling plays a critical role in mediating the psychostimulant and reinforcing properties of ketamine. 1 National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, 610041 Chengdu, People’s Republic of China. 2 Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, 264005 Yantai, People’s Republic of China.
    [Show full text]
  • British Journal of Nutrition (2009), 101, 457–464 Doi:10.1017/S0007114508024008 Q the Authors 2008
    Downloaded from https://www.cambridge.org/core British Journal of Nutrition (2009), 101, 457–464 doi:10.1017/S0007114508024008 q The Authors 2008 Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine . IP address: and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial 170.106.35.93 Mariangela Rondanelli1,2*, Annalisa Opizzi1,2, Sebastiano Bruno Solerte3, Rosita Trotti4, Catherine Klersy5 6 , on and Roberta Cazzola 29 Sep 2021 at 01:44:33 1Section of Human Nutrition and Dietetics, Department of Applied Health Sciences, Faculty of Medicine, University of Pavia, Pavia, Italy 2Endocrinology and Nutrition Unit, ASP, II.AA.RR, University of Pavia, ‘Istituto Santa Margherita’, Pavia, Italy 3Department of Internal Medicine, Geriatrics and Gerontologic Clinic, University of Pavia, ‘Istituto Santa Margherita’, Pavia, Italy 4Laboratory of Biochemical Chemistry, Neurological Institute ‘C. Mondino’, IRCCS, Pavia, Italy , subject to the Cambridge Core terms of use, available at 5Service of Biometry and Clinical Epidemiology, Fondazione IRCCS ‘Policlinico San Matteo’, Pavia, Italy 6Department of Preclinical Sciences ‘LITA Vialba’, Faculty of Medicine, University of Milan, Milan, Italy (Received 21 February 2008 – Revised 29 April 2008 – Accepted 20 May 2008 – First published online 1 July 2008) Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3- gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE– EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people.
    [Show full text]
  • Bioactivation Pathways of the Cb1r Antagonist Rimonabant
    DMD Fast Forward. Published on July 6, 2011 as DOI: 10.1124/dmd.111.039412 DMDThis Fast article Forward. has not been Published copyedited and on formatted. July 6, The2011 final as version doi:10.1124/dmd.111.039412 may differ from this version. DMD #39412 Bioactivation Pathways of the CB1r Antagonist Rimonabant Downloaded from Moa Andresen Bergström, Emre M. Isin, Neal Castagnoli Jr., and Claire E. Milne dmd.aspetjournals.org CVGI iMED DMPK, AstraZeneca R&D Mölndal, Sweden (M.A.B., E.M.I., C.E.M.); Department of Chemistry, Virginia Tech, and Virginia College of Osteopathic Medicine, Blacksburg, VA 24061 (N.C.) at ASPET Journals on October 1, 2021 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on July 6, 2011 as DOI: 10.1124/dmd.111.039412 This article has not been copyedited and formatted. The final version may differ from this version. DMD #39412 Running Title: Bioactivation Pathways of the CB1r Antagonist Rimonabant Corresponding Author: Dr. Moa Andresen Bergström, CVGI iMED DMPK, AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden. Tel.: +46317762551, Fax.: +46317763760, E-mail: [email protected]. Number of Text Pages: 18 Downloaded from Number of Tables: 2 Number of Figures: 6 dmd.aspetjournals.org Number of Schemes: 3 Number of References: 40 Number of Words in Abstract: 227 at ASPET Journals on October 1, 2021 Number of Words in Introduction: 604 Number of Words in Discussion: 1500 List of Nonstandard Abbreviations: ADRs, adverse drug reactions; BFC, 7-benzyloxy-4- trifluoromethylcoumarin; CYP, cytochrome P450; HFC, 7-hydroxy-4- (trifluoromethyl)coumarin; HLMs, human liver microsomes; IADRs, idiosyncratic adverse drug reactions; KCN, potassium cyanide; LC, liquid chromatography; LSC, liquid scintillation counting; MS, mass spectrometry; RAD, radiochemical detection; RLMs, rat liver microsomes; TDI, time-dependent inhibition 2 DMD Fast Forward.
    [Show full text]
  • Toxicology Solutions
    Toxicology Solutions Contents Biochip Array Technology Overview 04 Benefits 05 Testing Process 06 The Evidence Series 08 Evidence+ 10 Evidence 12 Evidence Investigator 14 Evidence MultiSTAT 16 Matrices 18 Test Menu 20 Customisable Test Menu 24 Catalogue Numbers 26 ELISA 28 Cross Reactivity 30 Technical Support 37 Ordering Information 38 Introduction Randox Toxicology aim to minimise laboratory workflow constraints whilst maximising the scope of quality drug detection. We are the primary manufacturer of Biochip Array Technology, ELISAs, and automated systems for forensic, clinical and workplace toxicology. Biochip Array Technology Moving away from traditional single analyte assays, Biochip Array Technology (BAT) boasts cutting-edge multiplex testing capabilities providing rapid and accurate drug detection from a single sample. Based on ELISA principles, the Biochip is a solid state device with discrete test regions onto which antibodies, specific to different drug compounds, are immobilised and stabilised. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen. Designed to work across a wide variety of matrices, this revolutionary multi- analyte testing platform allows toxicologists to achieve a complete immunoassay profile from the initial screening phase. Offering the most advanced screening technology on the market, Randox Toxicology has transformed the landscape of drugs of abuse (DoA) testing. Our unrivalled toxicology test menu is capable of detecting over 500 drugs and drug metabolites. 4 Benefits Simultaneous detection Multiplex testing facilitates simultaneous screening of various drugs and drug metabolites from a single sample. Accurate testing Biochip Array Technology has a proven high standard of accurate test results with CVs typically <10%. Small sample volume As little as 6μl of sample produces a complete immunoassay profile, leaving more for confirmatory testing.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Antiobesity and Anti-Inflammation Effects of Hakka Stir-Fried Tea Of
    food & nutrition research ORIGINAL ARTICLE Antiobesity and anti-inflammation effects of Hakka stir-fried tea of different storage years on high-fat diet-induced obese mice model via activating the AMPK/ACC/CPT1 pathway Qiuhua Li1, Xingfei Lai1, Lingli Sun1, Junxi Cao1, Caijin Ling1, Wenji Zhang1, Limin Xiang1, Ruohong Chen1, Dongli Li2* and Shili Sun1* 1Tea Research Institute, Guangdong Academy of Agricultural Sciences/Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation & Utilization, Guangzhou, China; 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China Popular scientific summary • We confirmed that HT treatment significantly reduced body weight and fat accumulation in major organs in high-fat diet-induced obese mice. • The effects of HT appear to be mediated by the activation of AMPK/ACC/CPT-1 pathway and further inhibiting lipogenesis. • Our findings suggest that HT may be used as a potential dietary strategy for preventing obesity and related metabolic disorder diseases. Abstract Background: As a typical representative of metabolic syndrome, obesity is also one of the extremely danger- ous factors of cardiovascular diseases. Thus, the prevention and treatment of obesity has gradually become a global campaign. There have been many reports that green tea is effective in preventing obesity, but as a kind of green tea with regional characteristics, there have been no reports that Hakka stir-fried tea (HT) of different storage years has a weight loss effect. Aims: The aim was to investigate the effect of HT in diet-induced obese mice. Methods: The mice were divided into five groups as follows: the control group received normal diet; the obese model group received high-fat diet; and HT2003, HT2008, and HT2015 groups, after the induction of obesity via a high-fat diet, received HT of different storage years treatment for 6 weeks, respectively.
    [Show full text]
  • The Endocannabinoid System and Psychiatric Disorders
    Experimental Neurology 224 (2010) 3–14 Contents lists available at ScienceDirect Experimental Neurology journal homepage: www.elsevier.com/locate/yexnr Review The endocannabinoid system and psychiatric disorders Daniela Parolaro a,b,⁎, Natalia Realini a, Daniela Vigano a,b, Cinzia Guidali a, Tiziana Rubino a a DBSF and Neuroscience Center, University of Insubria, Via A. da Giussano 10, 21052 Busto Arsizio (Varese), Italy b Zardi-Gori Foundation, via P.Cossa 1, Milan, Italy article info abstract Available online 29 March 2010 The present review summarizes the latest information on the role and the pharmacological modulation of the endocannabinoid system in mood disorders and its potential implication in psychotic disorders such as Keywords: schizophrenia. Endocannabinoid system Reduced functionality might be considered a predisposing factor for major depression, so boosting Depression endocannabinoid tone might be a useful alternative therapeutic approach for depressive disorders. The Anxiety picture regarding endocannabinoids and anxiety is more complicated since either too much or too little Schizophrenia anandamide can lead to anxiety states. However, a small rise in its level in specific brain areas might be beneficial for the response to a stressful situation and therefore to tone down anxiety. This effect might be achieved with low doses of cannabinoid indirect agonists, such as blockers of the degradative pathway (i.e. FAAH) or re-uptake inhibitors. Moreover several lines of experimental and clinical evidence point to a dysregulation of the endocanna- binoid system in schizophrenia. The high anandamide levels found in schizophrenic patients, negatively correlated with psychotic symptoms, point to a protective role, whereas the role of 2-arachidonoyl glycerol is still unclear.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Context-Specific Reversal of Cocaine Sensitization by the CB1 Cannabinoid Receptor Antagonist Rimonabant
    Neuropsychopharmacology (2008) 33, 2747–2759 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org Context-Specific Reversal of Cocaine Sensitization by the CB1 Cannabinoid Receptor Antagonist Rimonabant Gregory L Gerdeman*,1, Jason B Schechter1 and Edward D French1 1 Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, AZ, USA The CB cannabinoid receptor is implicated in the rewarding properties of many drugs of abuse, including cocaine. While CB receptor 1 1 involvement in the acute rewarding properties of cocaine is controversial, CB1 antagonists such as SR141716 (rimonabant) have clearly been found to prevent cue- and cocaine-elicited reinstatement of cocaine self-administration in rodents. Here we demonstrate the novel involvement of CB1 receptors in the maintenance of behavioral sensitization to cocaine in C57BL/6 mice. Consistent with previous reports, the induction of locomotor sensitization following repeated daily cocaine was not prevented by systemic pretreatment of either 9 rimonabant, D -tetrahydrocannabinol (THC), or a 1:1 mixture of THC and cannabidiol (CBD). In contrast, established cocaine sensitization was markedly disrupted following subchronic treatment with rimonabant alone. This effect was notably context-dependent, in that rimonabant did not diminish established cocaine sensitization if delivered in the home cage, but only if the rimonabant-injected mice were exposed to activity chambers previously paired with cocaine. These findings are
    [Show full text]
  • Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates
    1521-0103/372/1/119–127$35.00 https://doi.org/10.1124/jpet.119.261818 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 372:119–127, January 2020 Copyright ª 2019 by The American Society for Pharmacology and Experimental Therapeutics Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates Brian D. Kangas, Ani S. Zakarian, Kiran Vemuri, Shakiru O. Alapafuja, Shan Jiang, Spyros P. Nikas, Alexandros Makriyannis, and Jack Bergman Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (B.D.K., J.B.); Behavioral Biology Program, McLean Hospital, Belmont, Massachusetts (B.D.K., A.S.Z., J.B.); and Center for Drug Discovery, Northeastern University, Boston, Massachusetts (K.V., S.O.A., S.J., S.P.N., A.M.) Received July 29, 2019; accepted October 21, 2019 Downloaded from ABSTRACT Despite a growing acceptance that withdrawal symptoms can inhibitors AM3506 (0.3–5.6 mg/kg), URB597 (3.0–5.6 mg/kg), and emerge following discontinuation of cannabis products, espe- nonselective FAAH/MGL inhibitor AM4302 (3.0–10.0 mg/kg) cially in high-intake chronic users, there are no Food and Drug revealed that only agonists with CB1 affinity were able to Administration (FDA)–approved treatment options. Drug devel- reduce the rimonabant-like discriminative stimulus effects opment has been hampered by difficulties studying cannabis of withholding daily agonist treatment. Although the pres- jpet.aspetjournals.org withdrawal in laboratory animals. One preclinical approach that ent studies did not document physiologic disturbances has been effective in studying withdrawal from drugs in several associated with withdrawal, the results are consistent pharmacological classes is antagonist drug discrimination.
    [Show full text]
  • Original Article
    Original Article Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats Christian Doyon, Raphae¨l G. Denis, Elena-Dana Baraboi, Pierre Samson, Jose´e Lalonde, Yves Deshaies, and Denis Richard The effects of the cannabinoid-1 receptor (CB1) antagonist rimonabant on energy metabolism and fasting-induced hy- pothalamic-pituitary-adrenal (HPA) axis and neuronal ac- besity results from a prolonged energy imbal- tivation were investigated. Lean and obese Zucker rats ance during which intake exceeds expenditure. were treated orally with a daily dose of 10 mg/kg rimon- The difficulty to lose excess weight is tightly abant for 14 days. A comprehensive energy balance profile Olinked to the ability of the systems regulating based on whole-carcass analyses further demonstrated the energy balance to defend body weight. The complexity potential of CB1 antagonists for decreasing energy gain and redundancy within these systems, which involve an through reducing food intake and potentially increasing intricate network of peripheral signals and neuronal cir- brown adipose tissue thermogenesis. Rimonabant also re- cuits, constitute obstacles to finding potential targets for duced plasma glucose, insulin, and homeostasis model as- antiobesity treatments. Currently, one of the most prom- sessment of insulin resistance, which further confirms the ising targets for the pharmacological treatment of obesity ability of CB1 antagonists to improve insulin sensitivity. To test the hypothesis that rimonabant attenuates the effect is the cannabinoid-1 receptor (CB1). Rimonabant of fasting on HPA axis activation in the obese Zucker (SR141716), the first selective CB1 antagonist (1), acts as model, rats were either ad libitum–fed or food-deprived for a potent antiobesity agent when administered to diet- 8 h.
    [Show full text]
  • Potential Anxiogenic Effects of Cannabinoid CB1
    European Neuropsychopharmacology (2010) 20, 112–122 www.elsevier.com/locate/euroneuro Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142 K.S. Sink a, K.N. Segovia a, J. Sink a, P.A. Randall a, L.E. Collins a, M. Correa a,c, E.J. Markus a, V.K. Vemuri b, A. Makriyannis b, J.D. Salamone a,⁎ a Dept. of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA b Center for Drug Discovery, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA c Dept. Psicologia, Area de Psicobiologica, University of Jaume I, Castello, Spain Received 11 September 2009; received in revised form 30 October 2009; accepted 10 November 2009 KEYWORDS Abstract Rimonabant; Anxiety; Cannabinoid CB1 inverse agonists suppress food-motivated behaviors, but may also induce Depression; psychiatric effects such as depression and anxiety. To evaluate behaviors potentially related to Cannabinoid; anxiety, the present experiments assessed the CB1 inverse agonist AM251 (2.0–8.0 mg/kg), the Aversive motivation; CB1 antagonist AM4113 (3.0–12.0 mg/kg), and the benzodiazepine inverse agonist FG-7142 Open field; (10.0–20.0 mg/kg), using the open field test and the elevated plus maze. Although all three Plus maze drugs affected open field behavior, these effects were largely due to actions on locomotion. In the elevated plus maze, FG-7142 and AM251 both produced anxiogenic effects. FG-7142 and AM251 also significantly increased c-Fos activity in the amygdala and nucleus accumbens shell. In contrast, AM4113 failed to affect performance in the plus maze, and did not induce c-Fos immunoreactivity.
    [Show full text]